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Objective: Observational studies have demonstrated that type 2 diabetes is a stronger risk factor 
for coronary heart disease (CHD) in women compared with men. However, it is not clear 
whether this reflects a sex differential in the causal effect of diabetes on CHD risk or results from 
sex-specific residual confounding. 
Methods: Using 270 single nucleotide polymorphisms (SNPs) for type 2 diabetes identified in a 
type 2 diabetes genome-wide association study, we performed a sex-stratified Mendelian 
randomization (MR) study of type 2 diabetes and CHD using individual participant data in UK 
Biobank (N=251,420 women and 212,049 men). Weighted-median, MR Egger, MR-PRESSO 
and radial MR from summary-level analyses were used for pleiotropy assessment. 
Results: MR analyses showed that genetic risk of type 2 diabetes increased the odds of CHD for 
women (odds ratio [OR] 1.13, 95% confidence interval [CI] 1.08-1.18 per 1-log unit increase in 
odds of type 2 diabetes) and men (OR 1.21, 95% CI 1.17-1.26 per 1-log unit increase in odds of 
type 2 diabetes). Sensitivity analyses showed some evidence of directional pleiotropy, however, 
results were similar after correction for outlier SNPs.
Conclusions: This MR analysis supports a causal effect of genetic liability to type 2 diabetes on 
risk of CHD that is not stronger for women than men. Assuming a lack of bias, these findings 
suggest that the prevention and management of type 2 diabetes for CHD risk reduction is of 
equal priority in both sexes.
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Type 2 diabetes is a major risk factor for coronary heart disease (CHD)(1). Meta-analysis 
of observational studies demonstrates that type 2 diabetes is associated with a 44% greater relative 
risk of CHD in women compared with men(2). However, whether this reflects sex differences in 
the causal effect of type 2 diabetes on CHD or arises from confounding in observational studies is 
not well understood. Most observational studies adjust for traditional cardiovascular risk factors, 
yet novel biomarkers, social and behavioral factors, or women-specific risk factors, such as 
gestational diabetes, are not generally adjusted for and may explain some of the sex difference(3–
5). Sex differences in screening for and treatment of type 2 diabetes might also contribute to the 
greater excess risk of CHD conferred by type 2 diabetes among women relative to men(6). 
Mendelian randomization (MR) analysis exploits the natural random allocation of genetic 
variants at conception and is an increasingly utilized approach that can limit potential confounding 
in human research(7). Under the assumption that differences in the risk of disease arising from 
genotype mimic changes in the risk of disease acquired during life, MR can be used to detect causal 
effects. Recent MR studies support a causal relationship between genetic predisposition to type 2 
diabetes and CHD(8,9). However, these studies did not evaluate sex differences in the causal role 
of type 2 diabetes in CHD risk. If type 2 diabetes has a stronger causal effect on CHD risk in 
women compared with men, randomly allocated genetic variants that are risk alleles for type 2 
diabetes should also be more strongly associated with the risk of CHD in women than in men. 
Therefore, in this study we conducted a MR analysis to examine the sex-specific causal effect of 
the genetic risk of type 2 diabetes on CHD. 
Methods
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Data sources and study participants
Data from the UK Biobank and a consortium of genome-wide association studies (GWAS) 
for type 2 diabetes were used. The UK Biobank is a large prospective study of over 500,000 
individuals(10). Baseline data collection in the UK Biobank was conducted between 2006 and 
2010 across 22 assessment centers. Participants aged 37 to 73 completed touchscreen 
questionnaires, were interviewed by trained research nurses, had physical measurements taken and 
blood samples extracted and frozen. The presence of type 2 diabetes and CHD was self-reported 
at study baseline and confirmed by a trained nurse. Genotyping was performed using the 
Affymetrix UK BiLEVE Axiom array or the Affymetrix UK Biobank Axiom® array. A combined 
reference panel including UK10K samples was used for imputation(11). In accordance with the 
National Research Ethics Service and the governing Research Ethics Committee of UK Biobank, 
generic Research Tissue Bank approval was obtained, and study participants provided written 
informed consent(10). 
For the present study, we included individual-participant data on 463,469 UK Biobank 
participants who had concordant genetic and self-reported sex, who clustered with the Great 
Britain population in 1000 Genomes(12), whose genetic data was of sufficient quality(13), and 
who provided data on type 2 diabetes and CHD at baseline. Individuals with self-reported type 1 
diabetes, gestational diabetes only, or a diabetes diagnosis prior to the age of 18 were excluded. 
CHD was defined as self-reported history of angina or myocardial infarction, and linkage with 
hospital admissions data and the national death register was used to also identify incident 
diagnoses of CHD after the baseline visit using international classification of disease (ICD) 9 or 
10 codes (ICD9 410-414, ICD10 I20-I25) using follow-up data from recruitment through the end 
of February 2016 (mean 5.3 [SD 2.4] years), with N=3453 incident cases of CHD for women and 
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N=7420 incident cases for men. Myocardial infarction was also defined using the UK Biobank 
algorithm (https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/alg_outcome_mi.pdf).
Sex-specific summary-level data (ß-coefficients and standard errors) for the genetic 
contribution of type 2 diabetes risk were obtained from the European DIAMANTE 
(DIAbetes Meta-Analysis of Trans-Ethnic association studies) GWAS of type 2 diabetes cases 
(N=30,053 women and 41,846 men) and controls (N=434,336 women and 383,767 men) of 
European descent(14). The UK Biobank was excluded from GWAS estimates used in our analyses 
to avoid sample overlap.
Mendelian randomization and selection of SNPs for analyses
Mendelian randomization studies exploit the random assortment and independent 
inheritance of genetic variants in the population, which removes bias due to reverse causation and, 
if conducted appropriately, greatly reduces bias from residual or unmeasured confounding(15). 
However, three key assumptions must be met for genetic variants to serve as instrumental variables 
of an exposure in MR analyses (Supplemental Figure 1)(16). First, the variants must be associated 
with the exposure of interest; second, they must not be associated with confounders of the 
relationship between the exposure and the outcome; third, they must be independent of the 
outcome except for their association via the exposure. This third assumption relates to the issue of 
horizontal pleiotropy, in which one or more variants used in the instrumental variable influences 
the outcome via a pathway other than the exposure of interest. When horizontal pleiotropy has a 
net effect to bias the properties of the genetic instrument, the summary MR estimate can be biased 
either towards or away from the null. In this situation, horizontal pleiotropy leads to bias of the 
underlying ‘true’ causal effect and it is termed unbalanced horizontal, or directional, pleiotropy.
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In this study, we used data from the UK Biobank for individual-participant MR analysis. 
SNPs with significant associations (p<5x10-8) with type 2 diabetes from the sex-combined 
European DIAMANTE GWAS were selected (Supplemental Table 1). We assessed linkage 
disequilibrium (LD; r2>0.2) using PLINK(17) on a reference panel consisting of a random 
selection of 50,000 individuals from UK Biobank. Of 291 genome-wide significant SNPs from the 
European DIAMANTE GWAS, 270 were found in UK Biobank that were bi-allelic, were not in 
LD, and were not derived from GWAS that adjusted for body mass index. The SNPs were aligned 
to the same effect allele, and effect allele frequencies were checked for concordance. These 270 
SNPs were used to generate sex-specific weighted genetic risk scores as the instrumental variable 
for analyses(18). Individual SNPs were coded as 0, 1, or 2 depending on the number of type 2 
diabetes risk alleles. Each SNP was weighted by the corresponding sex-specific ß-coefficient 
obtained from the European DIAMANTE GWAS and then summed for all SNPs. This method 
reduces the risk of false positive results and bias toward the confounded observational association 
that may occur when all data (SNPs, exposure, outcome) are obtained from a single sample(19).
Statistical analysis
The strength of the genetic risk score as an instrument for type 2 diabetes was assessed 
using the F-statistic, where an F-statistic greater than 10 provides evidence against the possibility 
of bias arising due to a weak instrument(20). The association of sex-specific genetic risk scores 
with potential confounders was evaluated to assess the validity of the second assumption of MR 
(i.e., the genetic instrument is not associated with potential confounders) and was also compared 
with the observational association of type 2 diabetes status with potential confounders. 
Two-stage residual inclusion estimation using logistic regression at the second stage(21) 
and Terza standard errors(22) evaluated the association of the genetic risk scores for type 2 
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diabetes with CHD to estimate the odds of CHD per 1-log unit increase in the odds of type 2 
diabetes. This method includes first-stage residuals to correct for endogeneity(21), since 
application of traditional instrumental variable estimation approaches can be problematic for 
models including a binary exposure and a binary outcome(23). Models were adjusted for age, 
genotype array, and the first four principal components of ancestry. 
To assess and account for potential directional horizontal pleiotropy, we also performed 
summary-level MR analyses using SNP to type 2 diabetes estimates from DIAMANTE and SNP 
to CHD estimates in UK Biobank. For summary-level analyses, we obtained odds ratios (ORs) 
and 95% confidence intervals (CI) for the causal effect of a 1-log unit increase in the odds of 
genetic liability to type 2 diabetes on the odds of CHD using the weighted-median, MR Egger, 
Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO), and radial MR 
methods(24–27). The weighted-median method calculates a median of the SNP-specific causal 
estimates from the ratio method for each SNP(25). It has been shown to yield consistent estimates 
when the weights of up to half the instruments are not valid. The MR Egger method is equivalent 
to an inverse-variance weighted method but does not constrain the intercept to zero, and as such, 
the MR Egger estimate is the slope of the modified linear regression equation and the intercept 
represents the average pleiotropic effect across SNPs(24). A non-zero intercept provides evidence 
of unbalanced horizontal pleiotropy, and the slope of the regression coefficient should provide an 
estimate that is free from bias induced by unbalanced horizontal pleiotropy. Analyses were 
conducted using the ‘MendelianRandomization’ package in R Studio version 1.2.1206. The MR-
PRESSO test detects and corrects for horizontal pleiotropy and was performed using the 
‘MRPRESSO’ package in R(26). The first part of the test (MR-PRESSO global test) identifies the 
presence of horizontal pleiotropy, the second part corrects the causal estimate for identified 
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pleiotropy via outlier removal, and the third part (MR-PRESSO distortion test) tests whether the 
causal estimate significantly differs before and after correction. Additional analyses for pleiotropy 
assessment used radial MR Egger models to identify outliers in the UK Biobank analysis using the 
‘WSpiller/RadialMR’ package in R with modified second order weights(27), and analyses were 
repeated after exclusion of sex-specific outliers. P-values for the test of interaction for estimates 
from separate analyses was used to assess interaction by sex for each analysis(28). 
Results
Characteristics of the UK Biobank participants are presented in Table 1 and Supplemental 
Table 3. The mean age was 57 (standard deviation [SD] = 8) years and 46% of participants were 
men. The prevalence of type 2 diabetes was 4% in women and 8% in men. CHD was documented 
among 5% of women (N=12 716) and 12% of men (N=26 344), with myocardial infarction 
diagnosed in 1.5% of women (N=3807) and 6% of men (N=12 871). Both women and men with 
CHD were more likely to have traditional CHD risk factors (older age, type 2 diabetes, history of 
smoking, dyslipidemia, and hypertension) (Supplemental Table 3).
The sex-specific 270-SNP genetic risk score showed a strong association with type 2 
diabetes in both sexes (F-statistic 683 for women and 1005 for men, Supplemental Table 2), thus 
satisfying the first assumption of MR that the genetic instrument is associated with the exposure. 
We evaluated whether the apparent difference in instrument strength by sex was due to sex 
differences in the prevalence of type 2 diabetes. In a random subset of UK Biobank participants 
with 750 cases of type 2 diabetes for both women (N=18 493) and men (N=9100), the adjusted F 
statistic of 47 (R-squared 0.02) for women, and adjusted F statistic 45 (R-squared 0.03) for men 
were similar (data not shown). Thus, because the difference in instrument strength by sex is a 
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product of greater prevalence of type 2 diabetes in men, it is not likely to appreciably affect the 
comparative validity of estimates derived from MR analyses.
Potential confounders were similarly distributed across quartiles of the genetic risk score 
for both women and men (Table 2). Conversely, conventional observational analyses showed that 
type 2 diabetes status was strongly associated with all potential confounders assessed (Table 2), 
highlighting the need for instrumental variables in this setting.
Individual-participant results from TSRI analyses in UK Biobank showed similar effects 
of genetic risk of type 2 diabetes on CHD for each sex (OR 1.13, 95% CI 1.08-1.18 for women; 
OR 1.21, 95% CI 1.17-1.26 for men, Table 3). Sensitivity analyses using the weighted median 
method showed attenuated results (OR 1.04, 95% CI 1.00-1.08 for women; OR 1.06, 95% CI 1.03-
1.09 for men, Table 3). Using MR Egger, evidence of directional pleiotropy was observed in 
women (OR 1.01, 95% CI 0.96-1.06 and intercept 0.004, 95% CI 0.000 to 0.008, Table 3) and men 
(OR 1.00, 95% CI 0.96-1.04 and intercept 0.008, 95% CI 0.004 to 0.011, Table 3). Results from 
MR-PRESSO after outlier correction were slightly attenuated compared with those from TSRI 
analyses for both women (three outliers removed, OR 1.08, 95% CI 1.05-1.13) and men (five 
outliers removed, OR 1.13, 95% CI 1.10-1.17, Table 3). Analyses excluding SNPs from the genetic 
instrument that were identified as outliers by radial MR showed similar effect estimates as the 
TSRI results: OR 1.09, 95% CI 1.05-1.14 for women; OR 1.24, 95% CI 1.20-1.29 for men (Table 
3). We employed additional measures to assess for heterogeneity based on MR-Egger regression, 
including the Cochran Q-test and I-squared statistic. The Q-test showed evidence of heterogeneity 
in the effect of type 2 diabetes SNPs on CHD for both women (Q-statistic 395.8) and men (Q-
statistic 666.0). The I-squared (I2) statistic measures heterogeneity in the genetic associations with 
the exposure, and results (I2 84.7% for women and 87.1% men) showed some evidence of 
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heterogeneity in the associations of SNPs with type 2 diabetes. Such heterogeneity could be 
reflective of multiple causal pathways between type 2 diabetes and risk of CHD.
Discussion
In this MR study of the sex-specific effect of type 2 diabetes on CHD, we found that genetic 
predisposition to type 2 diabetes does not confer a greater excess risk of CHD for women than for 
men. While our results are consistent with previous sex-combined MR studies providing support 
for a causal role of type 2 diabetes in CHD risk(8,9), the finding that the causal effect of genetic 
liability to type 2 diabetes on CHD risk is not stronger for women than men is novel and differs 
from sex-specific estimates from the accumulated observational evidence(2). This includes a 
recent analysis in the UK Biobank, which showed a stronger association of type 2 diabetes with 
CHD for women than men(29). 
There are several potential explanations for the differences between the findings of our MR 
study and the observational evidence. As with any observational study, studies of sex differences 
in the association of type 2 diabetes with CHD may not have controlled for all relevant confounders 
or may have controlled for confounders that were poorly measured, leading to residual 
confounding. If this residual confounding differs between the sexes, a sex difference in the 
observational association of type 2 diabetes with CHD could arise. For example, men are typically 
at higher absolute risk of CHD, and the prevalence of many cardiovascular risk factors is higher 
for men than for women(1). However, cardiovascular risk factors including type 2 diabetes appear 
to confer a greater relative CHD risk for women than for men in observational analyses(29). 
Furthermore, among individuals with type 2 diabetes compared to those without type 2 diabetes, 
several studies have shown that the differences in cardiovascular risk factors including blood 
pressure, dyslipidemia, and particularly anthropometric variables are greater among women than 
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men(3,6). Although women generally display a more favorable cardiometabolic risk profile than 
men, this favorable risk profile declines and ultimately reverses as glycemic control 
deteriorates(30).
Yet observational evidence of sex differences in the association of other major risk factors 
with CHD is not universally observed, suggesting mechanisms other than confounding alone may 
be involved. An alternative explanation is that sex differences in the effect of diabetes on CHD 
risk seen in observational studies reflect the more adverse deterioration in cardiovascular risk 
profile along the glucose intolerance spectrum in women than men. A recent MR study showed 
that the association of BMI with the risk of diabetes was stronger for women than men(31). 
Accordingly, a pathway of type 2 diabetes progression and glycemic dysregulation that leads to 
more adverse complications of diabetes for women than men may underpin the observational 
findings, rather than a direct sex difference in the effect of diabetes on CHD risk.
Furthermore, women may be perceived as having lower cardiovascular risk and 
consequently, type 2 diabetes and comorbid cardiovascular risk factors may be treated less 
aggressively(32,33). Guidelines for the diagnosis and treatment of type 2 diabetes and CHD are 
not sex-specific; our results of a similar causal association of type 2 diabetes with CHD by sex 
would support the notion that for a given state of glycemic dysregulation and burden of 
cardiovascular risk factors, prevention and management of type 2 diabetes for the reduction of 
CHD risk should be of equal priority for both women and men. In addition, sex-specific 
confounders, such as reproductive factors including gestational diabetes, are rarely adjusted for in 
observational studies that include both sexes; this could inflate the association of type 2 diabetes 
with CHD in women if the cumulative duration of the exposure to diabetes is greater, on average, 
among women than men. Sex-specific residual confounding may therefore explain some of the 
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discrepancy between the MR and observational evidence. Alternatively, the discrepancy might 
arise if the MR analysis does not account for genetic variation in the risk of type 2 diabetes that 
derives from sex chromosomes, as the GWAS data includes only autosomal SNPs. For example, 
a recent MR study observed a causal association of genetically determined testosterone (X 
chromosome) with increased type 2 diabetes risk for women but not for men(34). Multiple other 
mechanisms could also play a role in conferring higher CHD risks for women with type 2 diabetes 
compared with men independent of glucose dysregulation or diabetes, including sex differences in 
microvasculature such as vascular responsivity to aldosterone(35).
The diagnosis of type 2 diabetes is defined by a cut-point along a continuum of glycemia 
that is based on the risk of associated complications such as retinopathy(36). Accordingly, an 
individual with borderline glycemia who is not yet diagnosed with type 2 diabetes may display 
phenotypic and genetic similarity when compared to an individual with diagnosed diabetes. 
Exposure misclassification of this type would tend to bias individual-participant MR estimates 
toward the null, leading to underestimation of the MR results. In our individual-participant MR, 
this scenario would only affect our conclusion when pre-diabetes affected a differential proportion 
of women and men in the study population. Of note, this should not influence summary-level MR 
results as the exposure is fully defined by genotype. 
There are several strengths of our study, including the use of MR, which under specific 
assumptions can be used to test the hypothesis that a particular risk factor is causal for an 
outcome(16). In accordance with the first assumption of MR, the sex-specific genetic risk scores 
were very strong instruments for type 2 diabetes for both women and men. Meeting the second 
and third assumptions of MR, the genetic risk scores were shown to be broadly independent of 
measured potential confounding factors. Furthermore, for both women and men, results of 
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sensitivity analyses after correction for outliers were similar to initial results. However, there are 
also limitations of our study. Although the genetic risk scores were strong instruments for type 2 
diabetes, our instruments may have been underpowered to detect modest differences in sex-
specific causal effects. Furthermore, our analysis used genetic risk scores derived from 270 
genome-wide significant type 2 diabetes SNPs in the sex-combined European DIAMANTE 
GWAS(14). Genetic instruments obtained from the SNPs that are associated with type 2 diabetes 
in sex-specific GWAS could also have been constructed. However, the European DIAMANTE 
GWAS observed only one significant sex-differentiated SNP(14) and thus, the impact of the use 
of a sex-combined instrument is unlikely to have changed our results substantially. Moreover, such 
an instrument would not permit direct comparison of sex differences in the overall genetic 
predisposition to type 2 diabetes, but instead compares the causal effect of two distinct sex-specific 
instruments on CHD risk.  
SNPs included in the genetic instruments for type 2 diabetes may affect CHD risk via 
pathways separate from their effect on type 2 diabetes risk, and these pathways could differ by 
sex. For example, there was some evidence of directional pleiotropy using MR Egger. However, 
the intercept for both men and women neared zero and MR-Egger generally lacks power. 
Moreover, results from outlier-robust sensitivity analyses were more similar to the overall results. 
This suggests that our primary results are in fact robust and that MR Egger results may have been 
influenced by sensitivity of this method to extreme outliers(37). 
These results might reflect multiple different scenarios(38), some of which may have 
downstream effects on type 2 diabetes risk and may differentially affect CHD risk by sex. Taken 
together, we cannot exclude a sex-specific causal effect via other pathways not captured in our 
genetic instrument. Of note, our instrumental variables for type 2 diabetes were derived from the 
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DIAMANTE GWAS effect estimates without adjustment for BMI since the influence of BMI on 
type 2 diabetes risk may be sex-differential(31). Considering the important role of BMI in type 2 
diabetes risk, adjusting for measures of adiposity in the type 2 diabetes GRS could bias a true 
differential effect of type 2 diabetes on CHD to the null. In addition, the UK Biobank and the 
European DIAMANTE GWAS used for our analyses include primarily European populations, and 
therefore, we cannot assess sex differences in the causal effect of type 2 diabetes with CHD across 
ethnicities. Furthermore, despite the large sample size of the UK Biobank, a low overall response 
rate of ~5.5% limits the generalizability of our results. Considering that the participating 
population is unlikely representative of the general UK population, as recently demonstrated(39), 
it is possible that our findings might be biased if there is a sex-specific selection bias that is 
associated with both the exposure and the outcome. Finally, a recent study demonstrated an 
association of autosomal loci with sex, which may introduce bias due to sex differences in study 
participation(40). If risk alleles for type 2 diabetes were associated with study participation in a 
sex-specific manner, this may have resulted in an inability to consistently detect a sex difference 
in the causal effect of type 2 diabetes with CHD in our MR analyses.
Conclusion 
The present MR analysis supports a causal effect of type 2 diabetes on the risk of CHD, 
with similar effects seen between women and men. In the absence of bias, these findings suggest 
that the prevention and management of type 2 diabetes for the reduction of CHD risk should be 
of equal priority for both women and men. 
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Table 1. Population Characteristics, UK Biobank (N=463 469)
Women (N=251 420) Men (N=212 049)
Age, mean (SD*), years 56.6 (7.95) 57.0 (8.12)
Array type, No. (%)                                         
  BiLEVE 24 920 (9.9) 24 897 (11.7)
  Axiom 226 489 (90.1) 187 147 (88.3)
Type 2 diabetes, No. (%) 9964 (4.0) 16 917 (8.0)
Body mass index, mean (SD), kg/m2 27.0 (5.1) 27.9 (4.2)
Waist circumference, mean (SD), cm 84.6 (12.5) 97.1 (11.4)
Smoking history, No. (%)
  Never 146 521 (58.3) 102 139 (48.2)
  Previous 81 252 (32.3) 82 970 (39.1)
  Current 22 574 (9.0) 26 011 (12.3)
Dyslipidemia, No. (%) 25 549 (10.2) 33 843 (16.0)
Hypertension, No. (%) 57 721 (23.0) 64 668  (30.5)
Systolic BP†, mean (SD), mmHg 135.3 (19.1) 141.1 (17.4)
Diastolic BP, mean (SD), mmHg 80.5 (9.9) 84.0 (9.9)
Coronary heart disease, No. (%) 12 716 (5.1) 26 344 (12.4)
  Myocardial infarction, No. (%) 3807 (1.5) 12 871 (6.0)
  Angina, No. (%) 4864 (1.9) 10 219 (4.8)
*SD: standard deviation; †BP: blood pressure
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Table 3. Mendelian randomization analysis of type 2 diabetes and risk of coronary heart disease, 
by sex, in UK Biobank*. Results indicate the increased risk of coronary heart disease per 1-log 
unit increase in genetic risk of type 2 diabetes (odds ratio [OR] and 95% confidence interval 
[CI]). 
Women Men
OR (95% CI) p-value OR (95% CI) p-value
Two-stage residual 
inclusion estimation†
1.13 (1.08-1.18) 5.84 x 10-08 1.21 (1.17-1.26) 2.31 x 10-24
Weighted-median‡. 1.04 (1.00-1.08) 0.067   1.06 (1.03-1.09) <0.001     
MR-Egger‡ 1.01 (0.96-1.06) 0.81 1.00 (0.96-1.04) 0.99
MR PRESSO (outlier-
corrected)‡
1.08 (1.05-1.13) 3.11 x 10-05 1.13 (1.10-1.17) 1.57 x 10-12
Sex-specific outliers 
removed†‡§
1.09 (1.05-1.14) 6.76 x 10-05 1.24 (1.20-1.29) 2.78 x 10-27
Intercept (95% CI) p-value Intercept (95% CI) p-value
MR-Egger (intercept)‡ 0.002 (0.000-0.008) 0.027 0.008 (0.004, 0.011) <0.001
Q-test‡ 395.8 666.0
I-squared‡ 84.7% 87.1%
*Genetic instrument comprised of N=270 SNPs for type 2 diabetes identified in European  
DIAMANTE GWAS. 
†Results from two-stage residual inclusion estimation using individual participant data  
and weighted genetic risk score in UK Biobank. Adjusted for age, genotype array, 
principle components of ancestry. P-value for interaction=0.02.
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‡Results from summary-level analyses using SNP-type 2 diabetes estimates from 
DIAMANTE GWAS (excluding UK Biobank) and SNP-CHD estimates from UK 
Biobank. P-values for interaction: weighted median 0.43; MR-Egger 0.76; MR-PRESSO 
0.07.
§Analysis with type 2 diabetes genetic instrument comprised of N=258 SNPs for women 
and N=245 SNPs for men, after SNPs identified as sex-specific outliers using radial MR 
excluded from genetic instrument. P-value for interaction <0.001.
Page 29 of 73
CONFIDENTIAL-For Peer Review Only
Diabetes Care
Supplem





ization: 1) The variants m
ust be associated w
ith the exposure of interest; 2) The variants m
ust not 
be associated w
ith confounders of the relationship betw
een the exposure and the outcom
e; 3) The variants m
ust be independent of the 
outcom
e except for their association via the exposure. SN
















ental Table 1. D
etails of the 270 single nucleotide polym
orphism
s (SN
P) used as a genetic instrum




eta coefficients and standard errors (SE) for the association of each SN
P w
ith type 2 diabetes 
from







ide association study. O
utlier SN

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplemental Table 2. Association of sex-specific genetic risk scores for type 2 diabetes with 
type 2 diabetes*. Genetic risk score comprised of 270 SNPs from the European DIAMANTE 
genome-wide association study. 
Women Men
F statistic 683 1077
R-squared 0.02 0.03
Odds ratio (95% 
confidence interval)†
1.70 (1.66-1.73) 1.70 (1.67-1.73)
*Adjusted for age, genotype array, and four principal components of 
ancestry.
†Odds ratios for the risk of type 2 diabetes per standard deviation increase in 
type 2 diabetes genetic risk score.
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Supplemental Table 3: Population Characteristics, UK Biobank (N=463 469), stratified by sex 
and coronary heart disease status.









Age, mean (SD*), years 56.3 (8.0) 61.6 (6.1) 56.3 (8.2) 61.5 (6.2)
Array type, No. (%)
  BiLEVE 23 257 (9.7) 1663 (13.1) 21 256 (11.4) 3641 (13.8)
  Axiom 215 436 (90.3) 11 053 (86.9) 164 446 (88.9) 22 701 (86.2)
Type 2 diabetes, No. (%) 8071 (3.3) 1893 (14.9) 11 705 (6.3) 5212 (19.8)
Body mass index, mean 
(SD), kg/m2
26.9 (5.1) 29.3 (5.8) 27.7 (4.2) 29.1 (4.6)
Waist circumference, 
mean (SD), cm
84.2 (12.3) 90.8 (13.8) 96.5 (11.1) 100.9 (12.0)
Smoking history, No. (%)
  Never 140 460 (58.8) 6061 (47.7) 93 156 (51.8) 8983 (34.1)
  Previous 76 325 (32.0) 4927 (38.7) 69 566 (37.5) 13 404 (50.9)
  Current 20 937 (8.8) 1637 (12.9) 22 237 (12.0) 3774 (14.3)
Dyslipidemia, No. (%) 21 515 (9.0) 4034 (31.7) 24 773 (13.3) 9070 (34.4)
Hypertension, No. (%) 51 335 (21.5) 6386  (50.2) 51 029 (27.5) 13 639 (51.8)
Systolic BP†, mean (SD), 
mmHg
135.1 (19.1) 140.1 (19.7) 141.0 (17.2) 141.4 (18.7)
Diastolic BP, mean (SD), 
mmHg
80.6 (9.9) 79.8 (10.5) 84.3 (9.8) 81.7 (10.6)
*SD: standard deviation; †BP: blood pressure
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